key: cord-0427790-zg2zq2ji authors: Zhang, Fan; Jonsson, Anna Helena; Nathan, Aparna; Wei, Kevin; Millard, Nghia; Xiao, Qian; Gutierrez-Arcelus, Maria; Apruzzese, William; Watts, Gerald F. M.; Weisenfeld, Dana; Kang, Joyce B.; Rumker, Laurie; Mears, Joseph; Slowikowski, Kamil; Weinand, Kathryn; Orange, Dana E.; Rangel-Moreno, Javier; Geraldino-Pardilla, Laura; Deane, Kevin D.; Tabechian, Darren; Ceponis, Arnold; Firestein, Gary S.; Maybury, Mark; Sahbudin, Ilfita; Ben-Artzi, Ami; Mandelin, Arthur M.; Nerviani, Alessandra; Rivellese, Felice; Pitzalis, Costantino; Hughes, Laura B.; Horowitz, Diane; DiCarlo, Edward; Gravallese, Ellen M.; Boyce, Brendan F.; Moreland, Larry W.; Goodman, Susan M.; Perlman, Harris; Holers, V. Michael; Liao, Katherine P.; Filer, Andrew; Bykerk, Vivian P.; Rao, Deepak A.; Donlin, Laura T.; Anolik, Jennifer H.; Brenner, Michael B.; Raychaudhuri, Soumya; Albrecht, Jennifer; Barnas, Jennifer L.; Bathon, Joan M.; Boyle, David L.; Bridges, S. Louis; Campbell, Debbie; Carr, Hayley L.; Chicoine, Adam; Cordle, Andrew; Curtis, Michelle; Dunn, Patrick; Forbess, Lindsy; Gregersen, Peter K.; Guthridge, Joel M.; Ivashkiv, Lionel B.; Ishigaki, Kazuyoshi; James, Judith A.; Keras, Gregory; Korsunsky, Ilya; Lakhanpal, Amit; Lederer, James A.; Li, Zhihan J.; Li, Yuhong; McDavid, Andrew; Meednu, Nida; Mantel, Ian; McGeachy, Mandy J.; Raza, Karim; Reshef, Yakir; Ritchlin, Christopher; Robinson, William H.; Sakaue, Saori; Seifert, Jennifer A.; Smith, Melanie H.; Scheel-Toellner, Dagmar; Utz, Paul J.; Weisman, Michael H.; Zhu, Zhu title: Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis date: 2022-02-28 journal: bioRxiv DOI: 10.1101/2022.02.25.481990 sha: 66b5b7a857b2fbe182bf5b3531635128f26e23b4 doc_id: 427790 cord_uid: zg2zq2ji Rheumatoid arthritis (RA) is a prototypical autoimmune disease that causes destructive tissue inflammation in joints and elsewhere. Clinical challenges in RA include the empirical selection of drugs to treat patients, inadequate responders with incomplete disease remission, and lack of a cure. We profiled the full spectrum of cells in inflamed synovium from patients with RA with the goal of deconstructing the cell states and pathways characterizing pathogenic heterogeneity in RA. Our multicenter consortium effort used multi-modal CITE-seq, RNA-seq, and histology of synovial tissue from 79 donors to build a >314,000 single-cell RA synovial cell atlas with 77 cell states from T, B/plasma, natural killer, myeloid, stromal, and endothelial cells. We stratified tissue samples into six distinct cell type abundance phenotypes (CTAPs) individually enriched for specific cell states. These CTAPs demonstrate the striking diversity of RA synovial inflammation, ranging from marked enrichment of T and B cells (CTAP-TB) to a congregation of specific myeloid, fibroblast, and endothelial cells largely lacking lymphocytes (CTAP-EFM). Disease-relevant cytokines, histology, and serology metrics are associated with certain CTAPs. This comprehensive RA synovial atlas and molecular, tissue-based CTAP stratification reveal new insights into RA pathology and heterogeneity, which could lead to novel targeted-treatment approaches in RA. we calculated the average of these cluster proportions within each RA CTAP and OA (Figure 278 2). These values are independent of cell-type abundance differences since they are calculated 279 relative to each cell type. For example, these values may reflect the relative abundance of IL1B + 280 macrophages among all myeloid cells, regardless of the total number of myeloid cells in a 281 sample. We observed reported differences in RA compared to OA, including an expansion of 282 sublining fibroblasts relative to lining fibroblasts, and expansion of IL1B + macrophages relative 283 to MERTK + macrophages. 284 285 CTAPs are characterized by specific cell states 286 We next set out to quantify how the composition of fine-grained cell states differed between 287 CTAPs. To accurately identify cell-states associated with individual CTAPs within each given 288 cell type, we used co-varying neighborhood analysis (CNA) 77 . CNA tests highly granular 289 "neighborhoods"-small groups of phenotypically similar cells-rather than larger clusters and 290 accounts for age, sex, and cell count per sample. CNA associations suggest that certain single-291 cell-resolution states within each cell type are more likely to be found in samples from one 292 CTAP than others. After identifying CTAP-associated neighborhoods, we defined the canonical 293 cell states that contain those neighborhoods to infer biologic meaning. In these analyses, we 294 use "expanded" and "depleted" to refer to changes in relative abundance within a cell type, but 295 notably these changes may not reflect a change in absolute cell numbers relative to total 296 number of cells. 297 298 We observed skewed T cell neighborhoods in CTAP-TB (permutation p=0.046) (Methods, 299 CX3CR1 OSM CXCR1 IFNG TNFSF9 TNF CXCL13 IL6R CXCR3 CXCR4 IFNGR2 CCR6 CXCR5 IFNGR1 CXCL9 OSMR IL6 PDGFRA CXCL12 EGFR CSF1 IL1B TGFB1 KDR PDGFB IL1R1 TNFSF10 LIFR CCL14 CCL23 CXCL10 CCL2 CXCL16 CXCL2 CXCL3 VEGFA TGFB2 TNFRSF1A CCL13 TGFBR1 CCR1 IL18 C T CCL3 OSM IL1B CCL4L2 CCL3L1 TGFB1 TNF LTB IL23A TNFSF8 CXCL13 TNFSF9 CCL5 IFNG TNFSF14 FLT3LG CCL28 XCL2 XCL1 TNFSF12 IL7 HBEGF INHBA VEGFA IL15 CXCL9 CXCL10 HGF CCL2 IL18 TNFSF13B CXCL16 CCL13 CCL18 IL10 CXCL2 CXCL3 TNFSF10 PDGFB CCL14 CCL23 CLCF1 CXCL1 TNFSF15 VEGFC VEGFB PDGFC TGFB2 IL6 PDGFA BMP2 CSF1 KITLG CXCL12 TGFB3 cell represents the linear best fit line and the shaded region represents the 95% confidence interval, NIH NIAMS R01AR073833 and R01AR073290 We especially acknowledge people in the AMP RA/SLE 1197 and D.H., recruited patients and obtained synovial tissues A. contributed to the procurement and processing of samples and design of the 1199 AMP study curated and analyzed histologic and clinical data. W.A. provided project 1201 management and curated histologic and clinical data designed and implemented the tissue disaggregation, cell sorting, and single-cell 1203 sequencing pipeline wrote the initial draft edited the draft. AMP: RA/SLE Network 1211 members contributed to this work by managing patient recruitment, curating clinical data, 1212 obtaining and processing synovial tissue samples, managing biorepositories, conducting 1213 histological or computational analysis, providing software code, providing website support, 1214 and/or providing input on data analysis and interpretation reports research support from Amgen, outside the submitted work. K.W. is a consultant 1220 for Mestag Therapeutics and Gilead Sciences and reports grant support from Gilead Sciences reports research support from Novartis and is a consultant for UCB, outside the 1222 submitted work. V.M.H. is a co-founder of Q32 Bio and has previously received sponsored 1223 research from Janssen and been a consultant for Celgene and BMS, outside the submitted 1224 work. A.F. reports personal fees from Abbvie GlaxoSmithKline, 1227 and Bristol-Myers Squibb and grant support from Janssen and Bristol-Myers Squibb, outside the 1228 submitted work is a founder for Mestag Therapeutics, a scientific advisor for 1231 All raw and processed data will be available upon acceptance. A cell browser website will be 1236 available to visualize our data and results Incidence and prevalence of rheumatoid 1261 arthritis, based on the 1987 American College of Rheumatology criteria: a systematic 1262 review Rheumatoid arthritis Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results 1265 from an inception cohort The pathogenesis of rheumatoid arthritis Synovial tissue research: a state-of-the-art review Reflections on 'older' drugs: learning new lessons in 1271 rheumatology Sustained biologic-free and drug-free remission in 1273 rheumatoid arthritis, where are we now? Rheumatoid arthritis therapy reappraisal: strategies, 1275 opportunities and challenges ACR70-disease activity score 1277 remission achievement from switches between all the available biological agents in 1278 rheumatoid arthritis: a systematic review of the literature Genetics of rheumatoid arthritis susceptibility, severity, and 1281 treatment response Advances in genetics 1283 toward identifying pathogenic cell states of rheumatoid arthritis Distinct HLA Associations with Rheumatoid Arthritis Subsets Defined by 1286 Transforming clinical trials in rheumatology: 1288 towards patient-centric precision medicine Fine mapping seronegative and seropositive rheumatoid arthritis to shared 1290 and distinct HLA alleles by adjusting for the effects of heterogeneity Genetic and genomic markers of anti-TNF 1293 treatment response in rheumatoid arthritis EULAR recommendations for the management of rheumatoid arthritis 1295 with synthetic and biological disease-modifying antirheumatic drugs: 2019 update American College of Rheumatology Guideline for the Treatment of 1298 Rheumatoid Arthritis Diagnosis and Management of Rheumatoid Arthritis: A Review Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and 1302 Rituximab versus tocilizumab in anti-TNF inadequate responder patients 1304 with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified Defining inflammatory cell states in rheumatoid arthritis joint synovial 1307 tissues by integrating single-cell transcriptomics and mass cytometry HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype 1312 expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation Pathologically expanded peripheral T helper cell subset drives B cells in 1315 rheumatoid arthritis Distinct synovial tissue macrophage subsets regulate inflammation and 1317 remission in rheumatoid arthritis Rheumatoid arthritis patients display B-cell dysregulation already in the 1319 naïve repertoire consistent with defects in B-cell tolerance Notch signalling drives synovial fibroblast identity and arthritis pathology PD-1hiCXCR5-T peripheral helper cells promote B cell responses 1323 in lupus via MAF and IL-21 Distinct phenotype of CD4+ T cells driving celiac disease identified 1325 in multiple autoimmune conditions Circulating CXCR5-PD-1hi peripheral T helper cells are associated with 1327 progression to type 1 diabetes Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic 1329 Macrophages in intestinal 1332 inflammation and resolution: a potential therapeutic target in IBD Genetics of autoimmune diseases: perspectives from genome-wide association 1335 studies The MHC locus and genetic 1337 susceptibility to autoimmune and infectious diseases Grading of chronic synovitis--a histopathological grading system for 1339 molecular and diagnostic pathology Fast, sensitive and accurate integration of single-cell data with Efficient and precise single-cell reference atlas mapping with Symphony Compromised function of regulatory T cells in rheumatoid arthritis 1345 and reversal by anti-TNFalpha therapy Identification of T helper type 1-1347 like, Foxp3+ regulatory T cells in human autoimmune disease Regulatory T cells produce profibrotic cytokines in the skin of 1350 patients with systemic sclerosis Plasticity of human regulatory T cells in healthy subjects and 1352 patients with type 1 diabetes The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c hi T-bet+ B cells in SLE Contribute to Pathogenic Responses in Systemic Lupus Erythematosus Polarized secretion of lysosomes at the B cell synapse couples antigen 1362 extraction to processing and presentation CD11c-Expressing B Cells Are Located at the T Cell/B Cell Border in 1364 Spleen and Are Potent APCs Expression of the Plasma Cell Transcriptional Regulator Blimp-1 Marginal zone B cells: From housekeeping function to 1369 autoimmunity? Human blood IgM 'memory' B cells are circulating splenic marginal zone B 1371 cells harboring a prediversified immunoglobulin repertoire Human marginal zone B cell development from early T2 progenitors Identification of a human splenic marginal zone B cell precursor with 1375 NOTCH2-dependent differentiation properties Ectopic germinal center formation in rheumatoid synovitis Differentiation of B cells in the 1379 nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis Tissue Determinants of Human NK Cell Development, Function, and 1382 Residence Innate lymphoid cells--a proposal for uniform nomenclature Innate lymphoid cells: major players in 1386 inflammatory diseases Subsets of ILC3-ILC1-like cells generate a diversity spectrum of innate lymphoid cells in human mucosal tissues Phagocytosis: An Immunobiologic Process Monocyte differentiation and antigen-1391 presenting functions Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial 1393 Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen Cross-tissue single-cell landscape of human monocytes and macrophages 1396 in health and disease Single-cell landscape of bronchoalveolar immune cells in patients with 1398 COVID-19 Osteopontin affects macrophage polarization promoting endocytic but not 1400 inflammatory properties Osteopontin Expression Identifies a Subset of Recruited Macrophages 1402 Distinct from Kupffer Cells in the Fatty Liver Single-cell RNA-seq reveals new types of human blood dendritic cells, 1404 monocytes, and progenitors Landscape and Dynamics of Single Immune Cells in Hepatocellular 1406 Cross-tissue, single-cell stromal atlas identifies shared pathological 1408 fibroblast phenotypes in four chronic inflammatory diseases Functionally distinct disease-associated fibroblast subsets in 1411 rheumatoid arthritis Cross-tissue organization of the fibroblast lineage Efficacy of tocilizumab in patients with moderate to severe active 1415 rheumatoid arthritis and a previous inadequate response to disease-modifying 1416 antirheumatic drugs: the ROSE study Interleukin-6 receptor inhibition with tocilizumab reduces disease 1418 activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic 1419 drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug 1420 therapy study Sarilumab Plus Methotrexate in Patients With Active Rheumatoid 1422 Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study Fibroblast pathology in inflammatory diseases Single-Cell Transcriptome Atlas of Murine Endothelial Cells An essential role for Prox1 in the induction of the lymphatic endothelial 1429 cell phenotype Single-cell mapping reveals new markers and functions of lymphatic 1431 endothelial cells in lymph nodes Co-varying neighborhood analysis identifies cell populations associated 1433 with phenotypes of interest from single-cell transcriptomics Helper Cell Biology: A Decade of Discovery and Diseases Synovial phenotypes in rheumatoid arthritis correlate with response to 1437 biologic therapeutics Synovial cellular and molecular signatures stratify clinical response to 1439 csDMARD therapy and predict radiographic progression in early rheumatoid arthritis 1440 patients New learnings on the pathophysiology of RA from 1442 synovial biopsies Spatial and functional heterogeneity of follicular helper T cells in 1446 autoimmunity The prognostic value of anti-cyclic citrullinated peptide antibody in patients 1448 with recent-onset rheumatoid arthritis The predictive value of anti-cyclic citrullinated peptide antibodies in 1450 early arthritis Blood vessel formation: what is its molecular basis? Single-cell analysis of germinal-center B cells informs on lymphoma cell 1454 of origin and outcome Human germinal center transcriptional programs are de-synchronized in B 1456 cell lymphoma An Integrated Multi-omic Single-Cell Atlas of Human B Cell Identity B cells in the pathogenesis of primary Sjögren syndrome Modified disease activity scores that include twenty-eight-joint counts Development and validation in a prospective longitudinal study of patients with rheumatoid 1463 arthritis Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on 1467 erythrocyte sedimentation rate Stromal cell markers are differentially expressed in the synovial tissue of 1469 patients with early arthritis Synovitis score: discrimination between chronic low-grade and high-grade 1471 synovitis Methods for high-dimensonal analysis of cells dissociated from 1473 cyropreserved synovial tissue Computational Identification of Cell 1475 Comprehensive Integration of Single-Cell Data Simultaneous epitope and transcriptome measurement in single cells Augmented implicitly restarted lanczos bidiagonalization 1481 methods UMAP: Uniform Manifold Approximation and Projection 1483 for Dimension Reduction Multimodally profiling memory T cells from a tuberculosis cohort identifies 1485 cell state associations with demographics, environment and disease CCA: An R Package to Extend Canonical 1488 Fitting Linear Mixed-Effects Models Using lme4 KEGG as a reference 1494 resource for gene and protein annotation Mixed-effects association of single cells identifies an expanded 1496 effector CD4+ T cell subset in rheumatoid arthritis In order to exclude low-quality synovial tissue samples from our multi-omics tissue processing 854 platform, we analyzed hematoxylin and eosin-stained slides of formalin-fixed, paraffin-855 embedded synovial tissue from each patient. At least six tissue fragments per patient were 856 included in the analysis to mitigate sampling bias. Synovial tissue was identified as previously 857 We quantified mRNA and antibody-derived tag (ADT) unique molecular identifier (UMI) counts 923 using Cell Ranger v3.1.0. First, raw BCL files were demultiplexed using cellranger mkfastq with 924 default parameters to generate FASTQ files. Then, these FASTQ files were aligned to the 925 GRCh38 human reference genome using Cellranger v3.1.0. Gene and ADT reads were 926 quantified simultaneously using cellranger count. 927 928 We show each QC step in Supplementary Figure 1 . Specifically, we performed consistent QC 930 to remove cells that expressed fewer than 500 genes or contained more than 20% of their total 931 UMIs mapping to mitochondrial genes, resulting in 403,596 cells. Then, we performed sample-932 level QC and removed samples with a low percentage (< 40%) of cells passing QC. We 933 removed three lower-quality samples (processed on the same day) with less than 40% of cells 934passing QC compared to 71% for other good quality samples. In the end, we obtained 393,344 935 cells from 82 samples that passed QC. For mRNA, we tested all mRNA features that were detected in more than 100 cells per donor 1040 with non-zero UMI counts. For each feature, we normalized counts in each pseudo-bulk sample 1041 into counts per million (CPM). Using linear models, we estimated the effect of each cluster for 1042 each feature on pseudo-bulk expression accounting for effects from the donor and the number 1043 of UMIs for each pseudo-bulk sample. Next, we used likelihood ratio tests (LRT) between two 1044 models: one that has the cluster variable, and another that doesn't have the cluster variable. 1045Finally, we selected a feature to be a cluster marker if it had a fold change greater than 2 and p-1046 value less than FDR 5%, which is p < 0.05/(number of tested genes × number of clusters). We 1047 repeated a similar analytical pipeline of normalization and scaling, feature selection, multi-modal 1048 dimensionality reduction, clustering, and differential expression analysis for T cells (p < 1.5x10 -1049 6 ), B cells and plasma cells (p < 1.9x10 -6 ), NK cells (p < 1.6x10 -6 ), myeloid cells (p < 1.8x10 -8 ), 1050 stromal cells (p < 4.3x10 -7 ), and endothelial cells (p < 1.2x10 -6 ), respectively. Furthermore, we 1051 annotated each cell-type cluster based on literature. We present cluster-specific marker genes 1052 and relative statistics in Supplementary Table 8. 1053 1054 We used the buildReferenceFromHarmonyObj() function from the Symphony 37 package to build 1056 integrated reference atlases for the global and cell-type specific atlases from the Harmony 1057 objects. To find concordance between cell types from our previous study 21 and this study, we 1058 used the Symphony mapQuery() function to map the 5,254 scRNA-seq query cells from Zhang 1059 et al, 2019 onto the global and respective cell-type reference atlases. We predicted reference 1060 cell types and states for the query cells using the knnPredict() function with k=5. For the cell-1061 type specific mapping, we excluded reference dendritic cells or mural cells because they were 1062 absent in the query. Note that because the gene expression matrices for the reference (this 1063 study) and query 21 datasets were generated using different versions of Gencode (version 19 vs. 1064 version 29, respectively), certain genes were named differently between the two datasets (e.g. 1065IL8 and CXCL8 are synonyms for the same gene ENSG00000169429). Because the mapping 1066 procedure uses overlapping gene names between reference and query, we "synced" the query 1067 gene names to the version 29 names using the shared Ensembl IDs (which do not change 1068 between Gencode versions) using the Gencode .gtf files. This converted 9,663 query gene 1069 names, and the synced expression matrix was used as input to mapping. 1070 1071 We identified six cell-type abundance phenotypes (CTAPs) based on hierarchical clustering on 1073 cell-type abundances for each CITE-seq patient sample. The differences across CTAPs are 1074 also reflected in the PCA space. We named each CTAP based on the cell types whose average 1075 proportions were higher among samples in the CTAP compared to their average across all 1076 samples (Supplementary Table 4) . To assess the stability of CTAPs, 1) We first bootstrapped 1077 the patient samples and clustered the resampled dataset, 2) For every original CTAP subgroup, 1078 we found the most similar cluster (based on Jaccard similarity) in each resampled clustering and 1079 recorded that value, giving us the maximum Jaccard similarity coefficient for each CTAP. The 1080 Jaccard similarity coefficient can be a value between 0 and 1, where 1 indicates complete 1081 overlap and 0 indicates no overlap between two sets of the clustering results, 3) We repeated 1082 the above two steps 1e4 times and calculated the mean Jaccard similarity coefficient. We 1083 performed this process on different possible numbers of patient subgroups ranging from 2 to 10, 1084 and evaluated the statistical stability retaining in-group similarity. We selected six clusters as 1085 CTAPs because they gave us relatively high stability (mean Jaccard similarity coefficient=0.727) 1086and also high granularity of biologically meaningful interpretations. To perform CNA, we used the tl.association() function in the cna Python package with default 1108 parameters and top four NAM-PCs as inputs, while controlling for the "age", "sex", and "number 1109 of cells per sample" as covariates. As CNA utilizes a permutation test, we determined a 1110 significant association based on a global permutation p < 0.05. For visualization of local 1111 associations, which indicate the particular neighborhoods driving a found global association, we 1112 used the 5% FDR threshold from CNA to determine which neighborhoods featured a locally 1113 significant correlation. In violin plots, we plotted this threshold as dotted lines. In UMAP plots, 1114 we colored neighborhoods that pass local significance based on the intensity of their correlation, 1115 with red indicating a higher positive correlation, while we colored neighborhoods that did not 1116 attain local significance as grey. We used a modified version of CNA, available on Github, which 1117 included the following features: 1) scaling the variance per neighborhood within the NAM 1118 inversely to the sample size of the source sample for that neighborhood's anchor cell such that 1119 total variance across all neighborhoods anchored on cells from the same sample sums to 1, and 11202) the addition of a pseudo-count, a small number that was added to each entry in the NAM. 1121Using CNA, we tested associations of cell neighborhoods that are associated with histology, 1122 ultrasound, clinical metrics, and also each CTAP group. The statistics are in Supplementary 1123 Table 9 . We provided a proof-of-concept framework to assign RA samples processed by other data 1148 modalities (e.g., flow cytometry) to the RA CTAPs generated from single-cell technology. 1149 Specifically for Figure 6E